Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo(Kindai University), Richard S. Finn, Shukui Qin(81th Hospital of PLA), Kwang‐Hyub Han(Severance Hospital), Kenji Ikeda(Toranomon Hospital), Fabio Piscaglia(University of Bologna), Ari David Baron(California Pacific Medical Center), Joong‐Won Park(National Cancer Center), Guohong Han(Air Force Medical University), Jacek Jassem(Gdańsk Medical University), Jean Frédéric Blanc(Université de Bordeaux), Arndt Vogel(Medizinische Hochschule Hannover), Д. В. Комов(Russian Cancer Research Center NN Blokhin), T.R. Jeffry Evans(University of Glasgow), Carlos López(Marqués de Valdecilla University Hospital), Corina E. Dutcus(Eisai (United States)), Matthew Guo(Eisai (United States)), Kenichi Saito(Eisai (United States)), Silvija Kraljevic(Eisai (United Kingdom)), Toshiyuki Tamai(Eisai (United States)), Min Ren(Eisai (United States)), Ann‐Lii Cheng(National Taiwan University Hospital)
Cited by 5,411Open Access
Abstract
Related Papers
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al.|International Journal of Cancer|2014|29k
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al.|New England Journal of Medicine|2008|12.9k